Terthera b.v.
Website to be confirmed.
About Terthera b.v.
Terthera b.v. sits in Radiopharma Developer, a segment Bracken sees as structurally important to the radiopharma value chain.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- Reuters Health · 2026-09-28Terthera B V expands cyclotron capacity to meet Lu-177 demandDetails remain limited but analysts read the move as a positioning play ahead of pivotal data.
- Endpoints News · 2026-02-07Terthera B V announces Phase II readout for lead theranostic candidateThe announcement comes amid tightening Mo-99 and Lu-177 supply.
- FierceBiotech · 2026-07-02Terthera B V appoints new Chief Medical Officer ahead of pivotal trialThe work builds on more than a decade of radiochemistry collaboration.
- BioPharma Reporter · 2026-08-25Terthera B V signs supply agreement to support late-stage trialsDetails remain limited but analysts read the move as a positioning play ahead of pivotal data.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
Actinium Pharmaceuticals
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Actinium Pharmaceuticals.
View profile →AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →Bayer Oncology
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Bayer Oncology.
View profile →